+44 (0) 1625 238610 info@alderleyanalytical.com

Speak to a scientist

2 + 11 =

Our founders

Elizabeth (Liz) Thomas FRSC – CEO
Liz is the CEO and a Co-founder of Alderley Analytical. She is an enthusiastic and effective senior executive with significant financial, general management and scientific experience gained in CROs and pharmaceutical companies.

In 2011 she joined ICON as Vice President and General Manager of the EU Bioanalytical business to ensure the sustained growth and profitability, customer focus and strategy development of the business. She was also responsible for all aspects of leadership, staff development, science and delivery for a group of 55 bioanalytical scientists working in the areas of large molecule bioanalysis, small molecule bioanalysis, biosimilars and biomarkers.

Prior to joining ICON, Liz was the Global Leader for Regulatory Bioanalysis in AstraZeneca. In this role she provided scientific, regulatory and strategic leadership globally for 112 scientists, located on six separate sites (UK, Sweden and US.) She also evaluated and recommended the size, shape and geographical presence for regulatory bioanalysis for global AZ transformation.  She developed a partnership model and led a team to evaluate and select a single, CRO partner for global clinical bioanalysis.

Liz is an established authority in bioanalysis in both the pharmaceutical and CRO industries. She has represented ICON, AstraZeneca and Alderley Analytical on the European Bioanalysis Forum (EBF) and has presented on bioanalytical and regulatory topics in the UK, US, China, India and Jordan.

Prior to joining AstraZeneca, Liz managed bioanalytical groups in Quintiles and Covance.

Liz is a qualified Analytical Chemist and is a Fellow of the Royal Society of Chemistry (FRSC) as well as the author/co-author of 9 peer-reviewed scientific papers.

Connect with Liz

Paul Holme BSc (Hons) MRQA – Operations Director
In a career spanning over 30 years, taking in both discovery and regulatory environments in the CRO and pharmaceutical industries, Paul has gained in-depth experience in toxicology, skin penetration, metabolism and bioanalysis. His expertise also includes developing and running LC-MS/MS, GC-MS/MS, HPLC-UV and ICP analytical methods.

Paul started his career in 1989 within ICI directing studies in toxicology and DMPK functions. It was during this time that he got the opportunity to lead the design and build of a new bioanalytical unit. In 2003, he moved to AstraZeneca and soon became the Group Manager of the Regulatory Bioanalysis Unit at Alderley Park. In 2011, he was promoted to the role of Associate Director of In-vivo Pharmacokinetics and Bioanalysis within AstraZeneca. Paul successfully led global change and harmonisation teams helping mould AstraZeneca’s future strategies.

In 2012 he took a senior position in a small CRO conducting regulatory skin penetration studies which provided valuable insight into running a small company.

Paul is recognised as an experienced scientist and a motivational leader, adept at building and managing high performing teams and known for maximising efficiency and productivity. He obtained his degree at Manchester Metropolitan University, holds a Prince II Practitioner certification and due to his extensive experience in GLP and GCP regulated departments, he has recently been accepted as a Member of the Research Quality Association (MRQA).

Connect with Paul

Claire Wildgoose BSc (Hons) – Projects Director
Before becoming part of the founding team of Alderley Analytical, Claire was a Bioanalytical Project Manager at ICON, where she managed small molecule, large molecule and biomarker projects. During this time, she designed and implemented an effective method for the collection and reporting of metrics, and had a key role in both the global harmonisation and continuous improvement teams.

Claire started her career as a laboratory scientist at Medeval and has over six years’ experience working as a bench top scientist. In 1999 she moved into the role of Project Leader, working on GLP, GCP and discovery projects. In 2002 Medeval was acquired by ICON and it was with ICON that she continued to develop her project management career.

Throughout her 21 years in the CRO industry, Claire has maintained an excellent customer focus and a proven track record of delivering high quality results on time to GLP/GCP regulatory standards, while focusing on cost, time and quality through the lifecycle of a project.

Claire has a first class honours degree in Applied Chemistry from Manchester Metropolitan University.

Connect with Claire

Sally Hannam BSc MRSC – Science Director
Another alumni of ICON, Sally was an Associate Director, responsible for the management of a team of LC-MS/MS scientists in the Manchester bioanalytical facility before joining forces with Liz, Paul and Claire to found Alderley Analytical.

Sally has extensive bioanalytical experience in small molecules, peptides, biomarkers and novel formulations, gained from a career in the CRO industry stretching over 25 years. She has been personally involved in the development and validation of over 300 methods to regulatory guidelines and has experience with a variety of extraction techniques and analytical platforms.

She started her career as a sandwich placement student at Medeval in 1986, where she developed and validated her very first bioanalytical method. She was recruited by Medeval following her graduation and was instrumental in developing quality systems that led to the laboratory gaining GLP accreditation in November 1996. She worked for Medeval in various roles until the company was acquired by ICON in 2002.

Sally has a large network of contacts in the pharmaceutical and biotechnology sectors and has collaborated and partnered with customers, as well as scientists from instrument manufacturing companies.

Sally has an honours degree in Applied Biological Sciences and is a Member of the Royal Society of Chemistry (MRSC).

Connect with Sally

Our board

Elizabeth (Liz) Thomas FRSC – CEO
Liz is the CEO and a Co-founder of Alderley Analytical. She is an enthusiastic and effective senior executive with significant financial, general management and scientific experience gained in CROs and pharmaceutical companies.

In 2011 she joined ICON as Vice President and General Manager of the EU Bioanalytical business to ensure the sustained growth and profitability, customer focus and strategy development of the business. She was also responsible for all aspects of leadership, staff development, science and delivery for a group of 55 bioanalytical scientists working in the areas of large molecule bioanalysis, small molecule bioanalysis, biosimilars and biomarkers.

Prior to joining ICON, Liz was the Global Leader for Regulatory Bioanalysis in AstraZeneca. In this role she provided scientific, regulatory and strategic leadership globally for 112 scientists, located on six separate sites (UK, Sweden and US.) She also evaluated and recommended the size, shape and geographical presence for regulatory bioanalysis for global AZ transformation.  She developed a partnership model and led a team to evaluate and select a single, CRO partner for global clinical bioanalysis.

Liz is an established authority in bioanalysis in both the pharmaceutical and CRO industries. She has represented ICON, AstraZeneca and Alderley Analytical on the European Bioanalysis Forum (EBF) and has presented on bioanalytical and regulatory topics in the UK, US, China, India and Jordan.

Prior to joining AstraZeneca, Liz managed bioanalytical groups in Quintiles and Covance.

Liz is a qualified Analytical Chemist and is a Fellow of the Royal Society of Chemistry (FRSC) as well as the author/co-author of 9 peer-reviewed scientific papers.

Connect with Liz

Paul Holme BSc (Hons) MRQA – Operations Director
In a career spanning over 30 years, taking in both discovery and regulatory environments in the CRO and pharmaceutical industries, Paul has gained in-depth experience in toxicology, skin penetration, metabolism and bioanalysis. His expertise also includes developing and running LC-MS/MS, GC-MS/MS, HPLC-UV and ICP analytical methods.

Paul started his career in 1989 within ICI directing studies in toxicology and DMPK functions. It was during this time that he got the opportunity to lead the design and build of a new bioanalytical unit. In 2003, he moved to AstraZeneca and soon became the Group Manager of the Regulatory Bioanalysis Unit at Alderley Park. In 2011, he was promoted to the role of Associate Director of In-vivo Pharmacokinetics and Bioanalysis within AstraZeneca. Paul successfully led global change and harmonisation teams helping mould AstraZeneca’s future strategies.

In 2012 he took a senior position in a small CRO conducting regulatory skin penetration studies which provided valuable insight into running a small company.

Paul is recognised as an experienced scientist and a motivational leader, adept at building and managing high performing teams and known for maximising efficiency and productivity. He obtained his degree at Manchester Metropolitan University, holds a Prince II Practitioner certification and due to his extensive experience in GLP and GCP regulated departments, he has recently been accepted as a Member of the Research Quality Association (MRQA).

Connect with Paul

Mark O’Brien – Board Member
Mark has over 20 years of IT experience and is now a serial investor in businesses that he believes provide market advantage through technology and resources. Current investments and board roles in addition to Alderley Analytical include a delivery technology business and a multi-channel online retailer.
Andy Ferns – Board Member
Andy is a business consultant and serial investor, having spent 25 years building and managing a highly successful manufacturing business, as well as advising high growth companies. As an investor director at Alderley Analytical, he brings significant skills in strategy and business development.
APV
Alderley Park Ventures (APV) is a healthcare and life sciences focused investment fund based in Alderley Park, Cheshire. The fund, which is managed by the BioCity Group, provides early stage and seed funding to start-ups on the Alderley Park site. APV’s first investment was in Alderley Analytical and the fund is represented by Sheila Andrews on the Board.
Spark
The North West Fund for Biomedical provides equity funding for businesses operating within the biomedical sector including pharmaceuticals, biotechnology, clinical research organisations and analytical services and sciences. SPARK Impact manages the North West Fund for Biomedical and is represented on the Board by Jerry Mobbs.

Our management team

Elizabeth (Liz) Thomas FRSC – CEO
Liz is the CEO and a Co-founder of Alderley Analytical. She is an enthusiastic and effective senior executive with significant financial, general management and scientific experience gained in CROs and pharmaceutical companies.

In 2011 she joined ICON as Vice President and General Manager of the EU Bioanalytical business to ensure the sustained growth and profitability, customer focus and strategy development of the business. She was also responsible for all aspects of leadership, staff development, science and delivery for a group of 55 bioanalytical scientists working in the areas of large molecule bioanalysis, small molecule bioanalysis, biosimilars and biomarkers.

Prior to joining ICON, Liz was the Global Leader for Regulatory Bioanalysis in AstraZeneca. In this role she provided scientific, regulatory and strategic leadership globally for 112 scientists, located on six separate sites (UK, Sweden and US.) She also evaluated and recommended the size, shape and geographical presence for regulatory bioanalysis for global AZ transformation.  She developed a partnership model and led a team to evaluate and select a single, CRO partner for global clinical bioanalysis.

Liz is an established authority in bioanalysis in both the pharmaceutical and CRO industries. She has represented ICON, AstraZeneca and Alderley Analytical on the European Bioanalysis Forum (EBF) and has presented on bioanalytical and regulatory topics in the UK, US, China, India and Jordan.

Prior to joining AstraZeneca, Liz managed bioanalytical groups in Quintiles and Covance.

Liz is a qualified Analytical Chemist and is a Fellow of the Royal Society of Chemistry (FRSC) as well as the author/co-author of 9 peer-reviewed scientific papers.

Connect with Liz

Paul Holme BSc (Hons) MRQA – Operations Director
In a career spanning over 30 years, taking in both discovery and regulatory environments in the CRO and pharmaceutical industries, Paul has gained in-depth experience in toxicology, skin penetration, metabolism and bioanalysis. His expertise also includes developing and running LC-MS/MS, GC-MS/MS, HPLC-UV and ICP analytical methods.

Paul started his career in 1989 within ICI directing studies in toxicology and DMPK functions. It was during this time that he got the opportunity to lead the design and build of a new bioanalytical unit. In 2003, he moved to AstraZeneca and soon became the Group Manager of the Regulatory Bioanalysis Unit at Alderley Park. In 2011, he was promoted to the role of Associate Director of In-vivo Pharmacokinetics and Bioanalysis within AstraZeneca. Paul successfully led global change and harmonisation teams helping mould AstraZeneca’s future strategies.

In 2012 he took a senior position in a small CRO conducting regulatory skin penetration studies which provided valuable insight into running a small company.

Paul is recognised as an experienced scientist and a motivational leader, adept at building and managing high performing teams and known for maximising efficiency and productivity. He obtained his degree at Manchester Metropolitan University, holds a Prince II Practitioner certification and due to his extensive experience in GLP and GCP regulated departments, he has recently been accepted as a Member of the Research Quality Association (MRQA).

Connect with Paul

Claire Wildgoose BSc (Hons) – Projects Director
Before becoming part of the founding team of Alderley Analytical, Claire was a Bioanalytical Project Manager at ICON, where she managed small molecule, large molecule and biomarker projects. During this time, she designed and implemented an effective method for the collection and reporting of metrics, and had a key role in both the global harmonisation and continuous improvement teams.

Claire started her career as a laboratory scientist at Medeval and has over six years’ experience working as a bench top scientist. In 1999 she moved into the role of Project Leader, working on GLP, GCP and discovery projects. In 2002 Medeval was acquired by ICON and it was with ICON that she continued to develop her project management career.

Throughout her 21 years in the CRO industry, Claire has maintained an excellent customer focus and a proven track record of delivering high quality results on time to GLP/GCP regulatory standards, while focusing on cost, time and quality through the lifecycle of a project.

Claire has a first class honours degree in Applied Chemistry from Manchester Metropolitan University.

Connect with Claire

Sally Hannam BSc MRSC – Science Director
Another alumni of ICON, Sally was an Associate Director, responsible for the management of a team of LC-MS/MS scientists in the Manchester bioanalytical facility before joining forces with Liz, Paul and Claire to found Alderley Analytical.

Sally has extensive bioanalytical experience in small molecules, peptides, biomarkers and novel formulations, gained from a career in the CRO industry stretching over 25 years. She has been personally involved in the development and validation of over 300 methods to regulatory guidelines and has experience with a variety of extraction techniques and analytical platforms.

She started her career as a sandwich placement student at Medeval in 1986, where she developed and validated her very first bioanalytical method. She was recruited by Medeval following her graduation and was instrumental in developing quality systems that led to the laboratory gaining GLP accreditation in November 1996. She worked for Medeval in various roles until the company was acquired by ICON in 2002.

Sally has a large network of contacts in the pharmaceutical and biotechnology sectors and has collaborated and partnered with customers, as well as scientists from instrument manufacturing companies.

Sally has an honours degree in Applied Biological Sciences and is a Member of the Royal Society of Chemistry (MRSC).

Connect with Sally

Justin Wildgoose – Associate Director, Business Development
Justin Wildgoose Associate Director, Business Development

Justin has been working in the CRO (Contract Research Organisation) and pharmaceutical industries for 20 years, and blends scientific expertise with commercial understanding of client requirements. As well as infectious enthusiasm we might add!

He began his career working as a bioanalyst in an early phase CRO where he was responsible for, amongst other things, the development of novel bioanalytical assays and sample analysis of study related samples from various pre-clinical/clinical phase studies. He also occupied the position of Study Director on numerous regulated studies.

In 2008, he made the career switch into business development and has held positions at various CROs around the globe including ICON, BASi, Simbec and Q2 Solutions before joining Alderley Analytical in 2017.

Connect with Justin

Jean Pearson MSc, MRQA – Head of Quality Assurance
Jean Pearson MSc, MRQA, Head of Quality Assurance

Jean Pearson is a Quality Assurance professional with over 30 years’ experience, previously working for Zeneca, then AstraZeneca as a Senior Auditor responsible for GLP and GCP in the laboratory.

During her career, she has been involved in the implementation and maintenance of effective compliance programmes for GLP as well as assurance of GCP in the laboratory including the development of a CAPA monitoring programme. As a QA/GLP compliance specialist, she supported the development of a GLP facility at a contract research organisation (CRO) in China, developing the internal GLP QA capability and conducting formal audits as well as providing help and advice on compliance issues to the CRO.

Jean has extensive audit experience of CROs, vendors and suppliers in the UK, US, Europe and Asia and has led external MHRA regulatory authority inspections in GLP facilities in the UK. Since joining Alderley Analytical in July 2016, she has been responsible for the development and management of the GLP and GCP audit programme.

Jean is a member of the Research Quality Association (RQA) and holds an MSc in Research Quality Management.

Connect with Jean